| 8.05 0.02 (0.25%) | 04-18 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 10.1 | 1-year : | 10.96 |
| Resists | First : | 8.64 | Second : | 9.39 |
| Pivot price | 8.43 |
|||
| Supports | First : | 7.44 | Second : | 6.19 |
| MAs | MA(5) : | 7.95 |
MA(20) : | 8.58 |
| MA(100) : | 7.08 |
MA(250) : | 6.98 |
|
| MACD | MACD : | -0.2 |
Signal : | 0 |
| %K %D | K(14,3) : | 30.8 |
D(3) : | 27.7 |
| RSI | RSI(14): 43.8 |
|||
| 52-week | High : | 10.75 | Low : | 5.01 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ GHSI ] has closed above bottom band by 32.3%. Bollinger Bands are 34.2% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 8.21 - 8.26 | 8.26 - 8.3 |
| Low: | 7.85 - 7.91 | 7.91 - 7.97 |
| Close: | 7.96 - 8.05 | 8.05 - 8.13 |
Guardion Health Sciences, Inc., together with its subsidiaries, operates as a specialty health sciences company in the United States. It operates in two segments, Medical Foods and Nutraceuticals, and Medical Devices. The company offers Lumega-Z, a medical food that replenishes and restores the macular protective pigment; and GlaucoCetin, a vision-specific medical food to support and protect the mitochondrial function of optic nerve cells, as well as improve blood flow in the ophthalmic artery in patients with glaucoma. It also provides MapcatSF, a medical device that measures the macular pigment optical density; CSV-1000 device that offers auto-calibrated tests to ensure the correct testing luminance and contrast levels; and CSV-2000, a digital standardized contrast sensitivity testing device, as well as develops, manufactures, and sells equipment and supplies for standardized vision testing under the VectorVision name for use by eye doctors in clinical trials, real-world vision evaluation, and industrial vision testing. In addition, the company develops ImmuneSF, a nutraceutical formulation, as well as a portfolio of nutraceutical products under the NutriGuard brand. Further, it distributes medical foods products through e-commerce in an online store, guardionhealth.com. Guardion Health Sciences, Inc. was founded in 2009 and is headquartered in San Diego, California.
Sun, 14 Apr 2024
Guardion Health Sciences (GHSI) Scheduled to Post Earnings on Monday - Defense World
Wed, 10 Apr 2024
Why Guardion Health Sciences, Inc. (NASDAQ:GHSI) Could Be Worth Watching - Simply Wall St
Tue, 09 Apr 2024
Guardion Health Sciences Updates Executive Compensation Plans - TipRanks.com - TipRanks
Fri, 29 Mar 2024
Guardion Health Sciences Announces Financial Results for the Year Ended December 31, 2023 - GlobeNewswire
Wed, 31 Jan 2024
GHSI Stock Quote Price and Forecast - CNN
Wed, 31 Jan 2024
Why Is Guardion Health (GHSI) Stock Up 66% Today? - InvestorPlace
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Outperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 1 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 22.2 (%) |
| Held by Institutions | 16.4 (%) |
| Shares Short | 140 (K) |
| Shares Short P.Month | 129 (K) |
| EPS | 0.11 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 6.38 |
| Profit Margin | 1.2 % |
| Operating Margin | -23.6 % |
| Return on Assets (ttm) | -14.7 % |
| Return on Equity (ttm) | 1.4 % |
| Qtrly Rev. Growth | 7.6 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 9.57 |
| EBITDA (p.s.) | -3.07 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -4 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 67.08 |
| PEG Ratio | 0 |
| Price to Book value | 1.25 |
| Price to Sales | 0.84 |
| Price to Cash Flow | -2.36 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|